| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
sales8178@energy-chemical.com |
(E)-5-(2-Bromovinyl)uracil manufacturers
|
| | (E)-5-(2-Bromovinyl)uracil Basic information |
| | (E)-5-(2-Bromovinyl)uracil Chemical Properties |
| Melting point | 189-194 °C (dec.)(lit.) | | density | 1.881 | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly, Heated) | | form | Solid | | pka | 7.54±0.10(Predicted) | | color | Pale Beige to Beige | | InChI | 1S/C6H5BrN2O2/c7-2-1-4-3-8-6(11)9-5(4)10/h1-3H,(H2,8,9,10,11)/b2-1+ | | InChIKey | BLXGZIDBSXVMLU-OWOJBTEDSA-N | | SMILES | Br\C=C\C1=CNC(=O)NC1=O |
| WGK Germany | 2 | | RTECS | UV9020500 | | Storage Class | 13 - Non Combustible Solids |
| | (E)-5-(2-Bromovinyl)uracil Usage And Synthesis |
| Chemical Properties | Beige Solid | | Uses | (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time. | | References | [1] De Clercq, et al. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine. J. Med. Chem. 29(2), 213-217 (1986). |
| | (E)-5-(2-Bromovinyl)uracil Preparation Products And Raw materials |
|